Humza Rashid

Drug prices ripple through public programs in ways that aren't obvious. A pricing decision that looks like good news for patients can quietly shift costs onto Medicaid and taxpayers.

• Studying how recent brand-name pricing decisions affect public payer spending.
• Focus on heart and diabetes drugs my future patients will take.
• Quantitative analysis of national pricing, rebate, and utilization data.

A cancer trial generates thousands of data questions from its sponsor. When nobody clearly owns a decision, they pile up, staff burn out, and patients wait longer to start treatment.

• Built and piloted OCTANE, which gives every decision an owner and an escalation path across regulatory, clinical, and data teams.
• Sort sponsor queries by source and type to find what causes the backlog.
• Track query burden, resolution time, protocol deviations, and time from consent to first treatment.

Millions of chest CTs are read for one question and then filed. The same scan holds information about the heart, liver, muscle, bone, and vessels that AI can now measure automatically.

• Reviewing 48+ studies across eight organ domains, with evidence from MESA, NLST, COPDGene, CARDIA, and Framingham.
• Building a five-axis framework for what a routine scan can predict beyond coronary calcium.

Some of the best cancer drugs weaken the heart. Stopping them protects the heart but can cost a patient their most effective treatment.

• First author of a JACC: Case Reports series on keeping patients on HER2-directed therapy with cardiology support.
• Research Associate at the Calhoun Cardiology Center since April 2025.

Ultrafine particles from traffic are small enough to reach the bloodstream, and no air quality standard regulates them. People who live beside highways breathe the most.

• Part of HAFTRAP, a randomized trial of in-home HEPA filters. Filtration lowered systolic blood pressure by 3 mm Hg in people with elevated readings (JACC).
• Leading the follow-up on whether filtration improves blood lipids (n=156).
• First author of a review of 21 studies on ultrafine particles and mortality, an Editor's Choice article in Toxics.